# CGeneTech (Suzhou, China) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cgenetech-suzhou-china-co

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.cgenetech.com.cn
- Total disclosed funding: $44M
- Latest round: Series C (Sep 3, 2024)
- Investors on record: 7

## About

Based in Suzhou, China and established in 2010, CGeneTech(Suzhou, China)Co., Ltd operates as a small molecule innovative drug developer that integrates R&D, production and clinical trial services. The founder, Qiang Yu, graduated from Peking University and The University of Kansas. The co-founder, Juping Ding, founded Beijing Mairuikai Medical Technology. It has been recognized as a Jiangsu Provincial Science and Technology Support Project Unit and its drugs has obtained clinical trial approval from the US FDA. The company also set up a Flash Release Preparation Engineering Technology Center. In September 2024, CGeneTech raised over CNY 100 million in series C funding from new investor Tongren Boda Capital.

The company's integrated drug research and development technology platforms include a target and drug molecule spatial interaction technology platform and a precision anti-cancer drug development platform. Its drugs include DPP-4 inhibitor senagliptin, CXCR4 antagonist CGT-1881, and FGFR/VEGFR dual-target inhibitor CGT-6321. The drugs developed by the company can be used to treat hypoglycemic, anti-cancer and autoimmune diseases.

CGeneTech generates revenue by developing innovative small molecule drugs that can be used to treat hypoglycemic, anti-cancer and autoimmune diseases.

The company will use the series C funding for the commercial production and sales of the Class 1 innovative drug product senagliptin and the clinical development of subsequent innovative product pipelines.

## Funding rounds

- Series C, Sep 3, 2024, $14M — Tongren Boda Capital
- Series A, Jul 30, 2019, $15M — Hongtai Aplus, ABC International Capital
- Series A, Dec 12, 2017, $15M — Qianrong Capital, Addor Capital, Tongren Boda Capital, Kington Capital
- Angel, Dec 2, 2012 — Oriza Holdings

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Angel
- Qianrong Capital (https://capitalatlas.ai/funds/qianrong-capital) — Series A
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series A
- Tongren Boda Capital (https://capitalatlas.ai/funds/tongren-boda-capital) — Series A, Series C
- Kington Capital (https://capitalatlas.ai/funds/kington-capital) — Series A
- Hongtai Aplus (https://capitalatlas.ai/funds/hongtai-aplus) — Series A
- ABC International Capital (https://capitalatlas.ai/funds/abc-international-capital) — Series A